Biotechnology Startup Law In Ukraine.
1. Introduction
Biotechnology Startup Law in Ukraine concerns the legal framework governing the establishment, financing, research, development, commercialisation and regulation of businesses operating in biotechnology.
Biotechnology startups may work in areas such as:
Genetic engineering and genome editing.
Pharmaceutical and vaccine development.
Medical biotechnology and diagnostics.
Agricultural biotechnology and genetically modified organisms (GMOs).
Synthetic biology and bioinformatics.
Stem-cell research and regenerative medicine.
Biopharmaceutical manufacturing.
Artificial intelligence-assisted drug discovery.
Clinical trials and personalised medicine.
Ukraine does not have one comprehensive statute exclusively governing biotechnology startups. Instead, these businesses operate under a combination of company law, intellectual property law, pharmaceutical regulation, public health legislation, biosecurity rules, data protection legislation, investment law and research regulations.
The principal legal challenge is balancing scientific innovation and commercial freedom with patient safety, biological security, environmental protection and protection of genetic information.
2. Principal legislation governing biotechnology startups
The following laws and regulations form the central legal framework.
| Legislation | Legal significance |
|---|---|
| Civil Code of Ukraine, 2003 | Company contracts, property, liability and intellectual property |
| Law No. 2275-VIII of 2018 | Limited and additional liability companies |
| Law No. 2465-IX of 2022 | Joint-stock companies |
| Law No. 1667-IX of 2021 | Diia.City special legal and tax regime |
| Law No. 3687-XII of 1993 | Protection of rights to inventions and utility models |
| Law No. 2469-IX of 2022 | Regulation of medicinal products |
| Law No. 3339-IX of 2023 | Genetic engineering and GMO regulation |
| Law No. 2297-VI of 2010 | Personal data protection |
| Law No. 2801-XII of 1992 | Fundamentals of Ukrainian healthcare legislation |
| Law No. 93/96-VR of 1996 | Foreign investment regime |
An important recent development is that Ukraine's Commercial Code ceased to be in force on 28 August 2025 under Law No. 4196-IX. Therefore, corporate structuring must take account of the reformed Civil Code-based framework and applicable special legislation.
Law Gratis+1
3. Establishment and incorporation of biotechnology startups
A. Limited liability company (LLC)
The limited liability company is a commonly used structure for biotechnology startups.
A biotechnology entrepreneur may establish an LLC for:
Pharmaceutical research and development.
Genetic-testing services.
Vaccine development.
Biotechnology manufacturing.
Laboratory research.
Agricultural biotechnology.
Medical-device development.
The Law on Limited and Additional Liability Companies, No. 2275-VIII, regulates incorporation, capital contributions, management, shareholder rights and corporate decision-making.
The company's articles of association should address:
Founders' ownership percentages.
Management and director powers.
Voting rights.
Investment and additional capital contributions.
Transfer of shares.
Intellectual property ownership.
Confidentiality and trade secrets.
Deadlock resolution.
Exit and acquisition arrangements.
B. Joint-stock company
A joint-stock company may be appropriate where a biotechnology enterprise requires substantial investment, multiple institutional investors or a structure suitable for larger-scale capital raising.
The Law on Joint-Stock Companies, No. 2465-IX, provides the relevant corporate governance framework.
C. Foreign incorporation and investment
Foreign investors can generally establish or acquire Ukrainian biotechnology companies, subject to applicable restrictions and regulatory requirements.
The Law on the Regime of Foreign Investments, No. 93/96-VR, provides the principal statutory framework.
Foreign investors should examine:
Foreign ownership and investment registration requirements.
Currency-control and banking requirements.
Beneficial ownership disclosure.
Sanctions and export-control restrictions.
Repatriation of investment proceeds.
Technology-transfer arrangements.
UNCTAD Investment Policy Hub+1
4. Diia.City and biotechnology startup incentives
Important innovation framework
Ukraine's Diia.City regime, established by Law No. 1667-IX, is particularly relevant to technology-intensive businesses.
A significant development occurred in February 2025, when the Ukrainian Government expanded eligibility to include companies engaged in research and development beyond the earlier IT and telecommunications categories.
The Government specifically identified biotechnology, genetic engineering and microelectronics as potential beneficiaries.
Cabinet of Ministers of Ukraine+1
Biotechnology companies undertaking qualifying R&D may therefore consider applying for Diia.City residency.
Potential advantages include:
A special corporate tax regime.
Investment-friendly corporate arrangements.
Flexible contractual arrangements for qualifying activities.
Special employment and gig-contract mechanisms where applicable.
Improved conditions for venture-capital investment.
However, Diia.City residency is not automatic. A company must satisfy the statutory eligibility conditions, including the applicable business-activity, employee or specialist, income and other requirements.
Importantly, Diia.City residency does not replace pharmaceutical licences, clinical-trial approvals, GMO authorisations or other sector-specific regulatory permissions.
5. Biotechnology research and development regulation
Biotechnology startups frequently conduct research before developing commercially marketable products.
Their activities may include:
Molecular biology experiments.
Genome sequencing.
Gene-editing research.
Cell-culture development.
Recombinant DNA research.
Vaccine research.
Drug discovery.
Stem-cell research.
Research must comply with applicable healthcare, laboratory safety, environmental, biosecurity and research-ethics requirements.
The startup should establish:
A documented research protocol.
Appropriate laboratory safety procedures.
Institutional ethics approval where required.
Biological-material storage procedures.
Research-data protection policies.
Animal-research safeguards where applicable.
Scientific quality-control procedures.
A particularly important distinction is between laboratory research and commercial medical use. A startup may be permitted to conduct a research activity but still require separate regulatory approval before manufacturing, distributing or administering a resulting medical product.
6. GMO and genetic engineering regulation
Ukraine's Law No. 3339-IX of 23 August 2023 establishes the statutory framework for genetic-engineering activities and state control over the market placement of genetically modified organisms and products.
The updated framework became operational on 16 September 2026, replacing the earlier 2007 GMO biosafety framework.
CIS Legislation+1
The law is particularly relevant to startups working on:
Genetically modified agricultural crops.
Genetically engineered microorganisms.
Gene-editing technologies.
Industrial biotechnology.
Genetically modified food products.
Biological research involving environmental release.
The regulatory framework distinguishes between activities in closed systems and activities involving potential contact with the environment.
Startups must assess whether their research or commercial activity requires registration, authorisation, notification, risk assessment or official supervision.
Legal principle: Commercial profitability cannot override human health, environmental protection and biological safety requirements.
7. Pharmaceutical and biological product approval
A biotechnology startup developing vaccines, gene therapies, biological medicines or recombinant proteins must comply with the applicable medicinal-product regulatory framework.
Law No. 2469-IX of 28 July 2022, On Medicinal Products, addresses:
Development of medicines.
Preclinical testing.
Clinical trials.
State registration.
Manufacturing standards.
Pharmaceutical quality control.
Importation and distribution.
Pharmacovigilance.
View details of the document+1
A startup developing a new biological medicine should generally consider the following development stages:
Discovery and laboratory research
Identification of a biological target and development of a potential therapeutic product.
Preclinical research
Evaluation of safety, toxicity, pharmacological properties and relevant biological effects.
Clinical-trial authorisation
Regulatory and ethics review before conducting human clinical trials.
Clinical testing
Investigation of safety and efficacy under approved trial protocols.
Marketing authorisation
Submission of the required scientific and regulatory documentation.
Manufacturing and distribution
Compliance with applicable Good Manufacturing Practice (GMP), quality and pharmacovigilance obligations.
A startup cannot lawfully market an unapproved medicinal product merely because its laboratory results appear promising.
8. Intellectual property rights and biotechnology patents
Intellectual property is one of the most valuable assets of a biotechnology startup.
A startup may develop:
New pharmaceutical compounds.
Gene-editing methods.
Diagnostic technologies.
Biological manufacturing processes.
Recombinant proteins.
Laboratory equipment.
Software for genomic analysis.
Novel agricultural biotechnology products.
The Law on Protection of Rights to Inventions and Utility Models, No. 3687-XII, is central to patent protection.
Important legal issues
A. Patent ownership
The startup must establish who owns an invention developed by its founders, employees, consultants, universities or research partners.
Employment and research agreements should clearly regulate ownership and assignment of intellectual property.
B. Patentability
An invention must satisfy applicable patentability requirements, including novelty, inventive step and industrial applicability.
Not every biological discovery or naturally occurring biological material can automatically be patented.
C. Trade secrets
Some biotechnology companies may prefer to protect manufacturing methods, laboratory protocols and proprietary research processes as confidential commercial information rather than disclose them in a patent application.
D. Licensing
A biotechnology startup may license its technology to pharmaceutical companies, hospitals, universities or international research organisations.
Licensing contracts should address royalties, geographical scope, exclusivity, sublicensing, patent maintenance and infringement enforcement.
9. Personal data and genetic information protection
Biotechnology startups frequently process highly sensitive information, including:
DNA sequences.
Genetic test results.
Medical histories.
Clinical-trial records.
Patient identification information.
Biological sample information.
Family genetic relationships.
Ukraine's Law No. 2297-VI on Personal Data Protection establishes the principal domestic framework.
Article 32 of the Constitution of Ukraine also protects privacy and personal and family life.
Startups should establish:
Lawful grounds for processing personal information.
Appropriate informed consent where required.
Data minimisation procedures.
Secure storage and access controls.
Restrictions on unauthorised disclosure.
Rules for secondary use of biological samples.
Appropriate international data-transfer safeguards.
For example, a genomic-testing startup cannot assume that consent to perform a genetic test automatically authorises the commercial sale of identifiable genetic information to pharmaceutical companies.
10. Clinical trials and research ethics
Biotechnology startups developing vaccines, biological medicines, cell therapies and gene therapies may need to conduct clinical trials.
Clinical research must comply with applicable Ukrainian legislation, Ministry of Health regulations, ethics requirements and internationally applicable research standards.
The relevant regulatory framework includes Ministry of Health Order No. 690 of 23 September 2009, as amended, concerning clinical trials of medicinal products.
Key legal requirements include:
Appropriate regulatory authorisation.
Ethics committee review.
Informed consent.
Participant confidentiality.
Medical supervision.
Adverse-event reporting.
Accurate research documentation.
Appropriate compensation and liability arrangements.
A startup cannot treat clinical-trial participants merely as commercial research resources. Their autonomy, dignity, safety and privacy must be protected.
11. Biotechnology startup funding and venture capital
Biotechnology startups generally require substantial funding because scientific development involves expensive laboratories, equipment, specialist personnel, clinical testing and regulatory compliance.
Common funding arrangements include:
| Funding source | Legal considerations |
|---|---|
| Angel investors | Share subscriptions and investment agreements |
| Venture capital | Equity financing and shareholder rights |
| Government grants | Eligibility and permitted use of funds |
| University partnerships | Research ownership and licensing |
| Pharmaceutical partnerships | Development and commercialisation agreements |
| Foreign investment | Foreign investment and currency regulations |
| Strategic investors | Technology-transfer and governance arrangements |
A. Shareholder agreements
A shareholder agreement should regulate:
Board appointment rights.
Voting arrangements.
Founder vesting.
Share-transfer restrictions.
Investor protections.
Anti-dilution arrangements.
Exit rights.
Dispute resolution.
B. Convertible investment
Investors may seek convertible instruments or other arrangements allowing an investment to convert into equity at a later stage.
The enforceability and structuring of these arrangements must be assessed under Ukrainian corporate and contract law.
C. University spin-offs
A university biotechnology startup must clarify whether its technology belongs to the founders, researchers, university or another research institution.
A written agreement should identify ownership, licensing rights, commercialisation rights and revenue sharing.
The Cambridge Judge Business School's research on Ukraine's venture-capital framework highlights continuing legal uncertainties concerning some venture-capital structures, including convertible debt and shareholder arrangements.
Cambridge Judge Business School+1
12. Employment law and scientific personnel
Biotechnology startups depend on specialised employees, including:
Molecular biologists.
Genetic engineers.
Pharmacologists.
Clinical researchers.
Bioinformaticians.
Laboratory technicians.
Biomedical engineers.
Regulatory affairs specialists.
Employment agreements should address confidentiality, intellectual property ownership, research misconduct, laboratory safety and post-employment obligations.
Particular attention should be given to inventions created by employees during their employment.
A startup should not assume that every invention developed by an employee automatically belongs to the company without examining the applicable statutory rules and contractual arrangements.
13. Product liability and corporate responsibility
Biotechnology businesses may face civil, regulatory and potentially criminal liability when their activities cause harm.
Examples include:
Defective biological medicines.
Unsafe diagnostic products.
Contaminated laboratory materials.
Improper clinical-trial procedures.
Unauthorised genetic testing.
Environmental damage caused by GMO release.
Misleading scientific claims.
Unlawful disclosure of patient information.
The Civil Code of Ukraine provides the general framework for contractual and non-contractual liability.
The startup should implement:
Product quality management.
Laboratory risk assessments.
Traceability systems.
Adverse-event monitoring.
Appropriate insurance.
Incident reporting.
Internal compliance audits.
14. Environmental protection and biosecurity
Biotechnology startups involved in genetic engineering, microorganism development or biological manufacturing must assess environmental and biosafety risks.
Relevant legal obligations may arise from the GMO legislation, environmental protection legislation, waste-management requirements and public health regulations.
A company conducting research involving genetically modified microorganisms should determine whether its activity falls within the closed-system regulatory framework.
A company proposing environmental release may face additional assessment, registration and control requirements.
Biosecurity compliance should also address:
Safe storage of biological materials.
Restricted laboratory access.
Transportation of biological samples.
Biological waste disposal.
Personnel training.
Emergency response procedures.
15. Important case laws relating to biotechnology startups in Ukraine
There is an important qualification: Ukrainian reported judgments directly concerning the incorporation of a biotechnology startup are limited. However, Supreme Court pharmaceutical-patent judgments establish important principles for biotechnology businesses, particularly those developing biological medicines, pharmaceutical products and patented technologies.
Case 1. Supreme Court – Case No. 910/17860/21 (8 December 2022)
Important patent precedent
Subject: Patent infringement before commercial marketing.
Background: A company challenged the use of inventions protected by its Ukrainian patents in connection with applications for state registration of medicinal products.
Legal issue: Could filing a medicinal-product registration application infringe patent rights even before the product entered commercial circulation?
Judicial reasoning: The Commercial Cassation Court recognised that filing an application for registration of a medicinal product incorporating another person's patented invention could constitute an infringement.
The patent owner did not necessarily have to wait until the competing medicine was sold.
Importance for biotechnology startups:
Conduct patent searches before developing products.
Obtain appropriate licences.
Avoid unauthorised use of patented pharmaceutical inventions.
Assess patent risks before regulatory submissions.
Source: Ukrainian Supreme Court, Case No. 910/17860/21.
court.gov.ua
Case 2. Supreme Court – Case No. 910/9215/21 (27 April 2023)
Subject: Caspofungin-Teva pharmaceutical patent dispute.
Background: The dispute concerned the proposed registration of Caspofungin-Teva. The patent owner argued that the product contained a compound protected by its Ukrainian patent.
Legal issue: Whether an application for state registration of a medicinal product using a protected invention could interfere with the patent owner's exclusive rights.
Judicial reasoning: The Supreme Court considered the regulatory application to be preparation for introducing the medicinal product into civil circulation. It concluded that the patent owner's rights could be infringed before actual commercial sales.
Importance for biotechnology startups:
This decision is particularly relevant to startups developing:
Antifungal biological medicines.
Pharmaceutical compositions.
Recombinant medicines.
Biopharmaceutical products.
It demonstrates the importance of freedom-to-operate assessments before commercial development.
Source: Ukrainian Supreme Court, Case No. 910/9215/21.
court.gov.ua+1
Case 3. Supreme Court – Case No. 910/8295/21 (14 December 2023)
Subject: Supplementary protection of pharmaceutical patent rights.
Background: The dispute concerned additional protection of a pharmaceutical invention and the application of Ukrainian patent legislation alongside international obligations.
Legal issue: Whether the patent owner could obtain supplementary protection in light of the applicable transitional patent-law provisions.
Judicial significance: The Supreme Court examined the relevant timing of the acquisition of the right to supplementary protection and the applicable legislative framework.
Importance for biotechnology startups:
This judgment is relevant to companies investing in medicines with lengthy development and regulatory approval periods.
It demonstrates why patent duration, regulatory delays and supplementary protection should be included in a startup's intellectual-property strategy.
Source: Ukrainian Supreme Court, Case No. 910/8295/21.
court.gov.ua+1
Case 4. Supreme Court – Case No. 911/165/18 (5 March 2026)
Subject: Bayer's rivaroxaban patent rights.
Background: The dispute concerned the importation of rivaroxaban pharmaceutical substance without the patent owner's authorisation.
Legal issue: Whether the patent owner could obtain judicial protection against unauthorised use of a patented pharmaceutical invention.
Judicial outcome: The Supreme Court dismissed the opposing party's cassation appeal and upheld important remedies in favour of Bayer, including protection against unauthorised use of the patented invention and seizure and destruction of infringing products.
Importance for biotechnology startups:
The case illustrates the importance of:
Patent clearance before importing pharmaceutical substances.
Securing technology licences.
Protecting patented biological and pharmaceutical products.
Maintaining supply-chain intellectual property compliance.
Source: Supreme Court judgment dated 5 March 2026, Case No. 911/165/18.
Newsroom
Case 5. Supreme Court – Case No. 910/9528/25 (30 April 2026)
Subject: Supplementary protection of a pharmaceutical patent during martial law.
Background: The dispute concerned Ukrainian Patent No. 85536 and the availability of supplementary protection for an invention relating to the active pharmaceutical ingredient of Gardasil 9.
Legal issue: Whether patent rights that expired during martial law remained effective under the special legislation governing intellectual property rights during that period.
Judicial outcome: The Commercial Cassation Court dismissed the cassation appeal and upheld the lower courts' conclusions supporting supplementary protection.
The Court recognised the compensatory purpose of supplementary protection for pharmaceutical inventions, given the time required to obtain regulatory authorisation.
Importance for biotechnology startups:
This case is relevant to companies developing vaccines and other biological medicines. It demonstrates the importance of examining patent-term extensions, supplementary protection and special wartime intellectual-property rules.
Source: Supreme Court judgment dated 30 April 2026, Case No. 910/9528/25.
court.gov.ua+1
16. Regulatory authorities supervising biotechnology startups
Several Ukrainian public institutions may exercise regulatory responsibilities depending on the nature of the startup's activities.
| Authority | Principal responsibility |
|---|---|
| Ministry of Health of Ukraine | Healthcare and pharmaceutical policy |
| State Expert Centre of the Ministry of Health | Evaluation of medicines and clinical-trial matters |
| State Service of Ukraine on Medicines and Drugs Control | Pharmaceutical regulatory supervision |
| Ministry of Economy | Economic and innovation policy |
| Ukrainian National Office of Intellectual Property and Innovations (UANIPIO) | Intellectual property administration |
| State Production and Consumer Service | Food safety and relevant consumer protection |
| Environmental authorities | Environmental protection and relevant GMO oversight |
| Ministry of Digital Transformation | Digital economy and Diia.City administration |
The exact competent authority depends on the product and activity involved.
17. Major legal challenges facing biotechnology startups
A. Regulatory uncertainty
Biotechnology products may fall under several different regulatory categories. A product involving genetic engineering, medical diagnostics and pharmaceutical development may require compliance with multiple legal regimes.
B. High research and development costs
Biotechnology requires long development periods, specialised equipment and significant financial investment.
C. Intellectual property disputes
Disputes can arise between founders, universities, research institutions, employees and pharmaceutical companies over ownership of inventions.
D. Clinical-trial liability
Startups may face legal consequences for inadequate informed consent, unsafe research procedures or failure to report adverse events.
E. Genetic privacy
Genomic information can reveal information about individuals and their biological relatives. Improper disclosure can cause serious privacy and discrimination concerns.
F. Wartime operational risks
The war creates additional concerns involving laboratory infrastructure, insurance, supply-chain continuity, international investment, transportation of biological materials and research continuity.
G. International regulatory recognition
A product authorised in another country is not automatically authorised for commercial distribution in Ukraine. Startups must assess Ukrainian regulatory requirements and relevant international recognition arrangements.
18. Practical legal compliance checklist for a biotechnology startup
A biotechnology founder should consider the following steps before commencing commercial operations.
Startup legal compliance checklist
Compliance progress
0/15
Select an appropriate Ukrainian company structure
Register the company and identify its beneficial owners
Prepare articles of association and founder agreements
Clarify ownership of inventions and research results
Conduct patent searches and freedom-to-operate assessments
Determine whether Diia.City residency is available
Identify applicable pharmaceutical or medical-device requirements
Obtain required clinical-trial and ethics approvals
Assess GMO and biosafety obligations
Implement personal and genetic data protection procedures
Establish laboratory safety and quality-management systems
Prepare investment, licensing and research agreements
Establish product liability and insurance arrangements
Implement environmental and biosecurity compliance
Review foreign investment, sanctions and export-control requirements
Reset checklist
19. International legal framework
Ukrainian biotechnology startups may also be affected by international treaties and standards.
Important instruments include:
TRIPS Agreement: Protection and enforcement of intellectual property rights.
European Patent Convention: European patent protection, subject to applicable territorial and procedural requirements.
Convention on Human Rights and Biomedicine (Oviedo Convention): Human dignity, consent and protection in biomedical research, where applicable to Ukraine's treaty obligations.
Convention on Biological Diversity: Conservation and sustainable use of biological diversity.
Cartagena Protocol on Biosafety: International biosafety framework concerning living modified organisms.
European clinical-research standards: Relevant where Ukrainian research participates in multinational clinical trials.
These instruments help connect Ukrainian biotechnology regulation with international scientific research, investment and commercialisation.
20. Conclusion
Biotechnology Startup Law in Ukraine is an interdisciplinary legal framework connecting corporate governance, intellectual property, pharmaceutical regulation, clinical research, environmental protection, biosecurity and investment law.
The most important legislation includes the Civil Code of Ukraine, Law No. 2275-VIII on Limited Liability Companies, Law No. 1667-IX establishing Diia.City, Law No. 3687-XII on inventions and utility models, Law No. 2469-IX on Medicinal Products and Law No. 3339-IX governing genetic engineering and GMOs.
The Supreme Court judgments in Cases No. 910/17860/21 and 910/9215/21 demonstrate the importance of patent protection even before a competing medicinal product reaches the market. The 2026 decisions in Cases No. 911/165/18 and 910/9528/25 further illustrate the importance of pharmaceutical patent enforcement and supplementary protection.
Ultimately, the development of biotechnology startups in Ukraine depends on the ability to combine scientific innovation, lawful commercialisation, investment protection, research ethics and public safety.
21. Important legislation and judicial research references
For academic research, dissertations and further case-law analysis, the following primary resources are useful:
Official Ukrainian legislation database.
Unified State Register of Court Decisions.
Cambridge research on venture capital in Ukraine.
Academic qualification: The cited Supreme Court cases primarily concern pharmaceutical patents and are analogous authorities for biotechnology startups, not judgments establishing a separate legal regime for startup incorporation. The legislation and its amendments should be checked in their official Ukrainian versions before relying on them in litigation or commercial transactions.

comments